Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF and Peg-IFN-alpha-2b for Relapsed Leukemia/MDS Post-Transplant
NCT00548847Phase 2Completed
- Sponsor
- Emory University
- Start
- Jan 2007
- Primary completion
- Mar 2015
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of sargramostim, peginterferon alfa-2b in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), sponsored by Emory University. Started Jan 2007; status: completed.
02
Drugs
sargramostimpeginterferon alfa-2b
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00548847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00548847.